verb \ pruh-tay-go\ Latin “to protect”
Praetego is a pharmaceutical company committed to protecting patients from neurodegenerative diseases associated with aging, starting with Alzheimer’s disease.
Praetego’s novel small molecule series, the Amadorins, have a unique and powerful mechanism of action with the potential to provide systemic protection against a known driver of the chronic diseases of aging.
Praetego was founded on rigorous and extensive science and the desire to offer a potent oral drug for neurodegenerative diseases associated with aging. Our proprietary small molecule technology inhibits an established driver of disease pathology in neurodegeneration, diabetic microvascular disease, and aging.
At Praetego, we are committed to addressing neurodegenerative diseases associated with aging. Praetego’s management team led the discovery and development of the Amadorins. Our clinicians are leaders in the field of neurology and neurodegeneration. Complimented by guidance from industry veterans, the Praetego team has extensive technical and operational experience in developmental stage drug companies.
Praetego’s Amadorins have demonstrated preclinical proof of efficacy in Alzheimer’s disease and Diabetic Peripheral Neuropathy. We have two candidates under development, lead PTG-630 and PTG-670. Our Alzheimer's Disease program leads the pipeline and is complemented by our efforts in Diabetic Peripheral Neuropathy and Diabetic Retinopathy.
March 1, 2023
Praetego Inc, a pharmaceutical company protecting patients from neurodegenerative diseases related to aging, is pleased to announce a $0.3M STTR award from the National Eye Institute. The Phase 1 award advances Praetego’s lead candidate, PTG-630, into preclinical proof of concept in diabetic retinopathy.
October 4, 2022
Praetego Inc, a pharmaceutical company committed to protecting patients from neurodegenerative diseases related to aging, is pleased to announce a $2.5M STTR award from the National Institute of Aging (NIA). The Phase 2 award advances Praetego’s lead candidate, PTG-630, against Alzheimer’s disease (AD).
